NCT04646655View on ClinicalTrials.gov

Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

October 16, 2022

Study Completion Date

April 30, 2023

Conditions
Covid19Thrombosis
Interventions
DRUG

Enoxaparin

subcutaneous injections

Trial Locations (1)

20157

ASST Fatebenefratelli Sacco, Milan

All Listed Sponsors
collaborator

Massimo Arquati

UNKNOWN

collaborator

Riccardo Colombo

UNKNOWN

collaborator

Umberto Russo

UNKNOWN

collaborator

Manuela Nebuloni

UNKNOWN

collaborator

Spinello Antinori

UNKNOWN

lead

ASST Fatebenefratelli Sacco

OTHER

NCT04646655 - Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19 | Biotech Hunter | Biotech Hunter